Sep 30, 2022

Hannon Armstrong Q3 2022 Earnings Report

Reported an increase in Distributable EPS and GAAP EPS, driven by a larger portfolio and changes in asset securitization.

Key Takeaways

Hannon Armstrong reported strong Q3 2022 results, with GAAP EPS of $0.38 and Distributable EPS of $0.49, representing a 20% year-over-year increase. The company closed $273 million of investments and affirmed its guidance for Distributable Earnings Per Share growth.

GAAP EPS was $0.38, compared to $(0.04) for the same period in 2021.

Distributable EPS was $0.49, a 20% increase compared to $0.41 in the same period in 2021.

Distributable Net Investment Income increased by 36% year-over-year to $43.4 million.

The company reaffirmed its guidance for Distributable Earnings Per Share to grow at a compound annual rate of 10% to 13% from 2021 to 2024.

Total Revenue
$34.3M
Previous year: $26.2M
+30.7%
EPS
$0.49
Previous year: $0.41
+19.5%
Dividend per share
$0.375
Previous year: $0.35
+7.1%
Gross Profit
$60.1M
Previous year: $48.9M
+23.0%
Cash and Equivalents
$273M
Previous year: $413M
-34.0%
Total Assets
$4.5B
Previous year: $3.94B
+14.1%

Hannon Armstrong

Hannon Armstrong

Forward Guidance

The Company expects that annual distributable earnings per share will grow at a compounded annual rate of 10% to 13% from 2021 to 2024, relative to the 2020 baseline of $1.55 per share, which is equivalent to a 2024 midpoint of $2.40 per share. The Company also expects growth of annual dividends per share to be at a compounded annual rate of 5% to 8%.

Positive Outlook

  • Yield on its existing portfolio
  • Yield on incremental portfolio investments, inclusive of the Company’s existing pipeline
  • The volume and profitability of transactions
  • Amount, timing, and costs of debt and equity capital to fund new investments
  • Changes in costs and expenses reflective of the Company’s forecasted operations

Challenges Ahead

  • General interest rate and market environment
  • Ongoing and future impact of COVID-19
  • Speed and efficacy of vaccine distribution on economic conditions
  • The regulatory environment
  • The dynamics of the markets in which we operate